Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis

Pharmacology Research and Perspectives

Volumn 2, Issue 6, 2014, Pages

  Zhuang, Jianguo ^a   Laing, Naomi ^b   Oates, Melanie ^a   Lin, Ke ^a,c   Johnson, Gillian ^a,c   Pettitt, Andrew R ^a,c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Apoptosis; CD40 stimulation; CLL; IAPs; TRAIL

Indexed keywords

AZD 5582; CD40 ANTIGEN; DEATH RECEPTOR; DEXAMETHASONE; FLUDARABINE; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD; CELL SUSPENSION; CELL VIABILITY ASSAY; CENTRIFUGATION; CHEMILUMINESCENCE IMMUNOASSAY; CHRONIC LYMPHOID LEUKEMIA CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DENSITOMETRY; DRUG SENSITIZATION; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STIMULATION; WESTERN BLOTTING;

EID: 84929148371     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.81     Document Type: Article

References (60)

1. Baud V, Karin M (2009). Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33–40.
2. Beug ST, Cheung HH, Lacasse EC, Korneluk RG (2012). Modulation of immune signalling by inhibitors of apoptosis. Trends Immunol 33: 535–545.
3. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endi E, et al. (2005). Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106: 2018–2025.
4. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW (1997). Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 94: 10057–10062.
5. Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, et al. (2002). Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 3854–3859.
6. Consoli U, El-Tounsi I, Sandoval A, Snell V, Kleine HD, Brown W, et al. (1998). Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 91: 1742–1748.
7. Dicker F, Kater AP, Fukuda T, Kipps TJ (2005). Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood 105: 3193–3198.
8. Eckelman BP, Salvesen GS, Scott FL (2006). Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7: 988–994.
9. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L, et al. (2005). BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 106: 4131–4138.
10. Frenzel LP, Patz M, Pallasch CP, Brinker R, Claasen J, Schulz A, et al. (2011). Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br J Haematol 152: 191–200.
11. Fulda S (2007). Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther 7: 1255–1264.
12. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ (2000). Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164: 2200–2206.
13. Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, et al. (2002). Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 32: 1403–1413.
14. Ghosh S, Hayden MS (2008). New regulators of NF-kappaB in inflammation. Nature Rev Immunol 8: 837–848.
15. Giam M, Huang DC, Bouillet P (2008). BH3-only proteins and their roles in programmed cell death. Oncogene 27(Suppl. 1): S128–S136.
16. de Graaf AO, van Krieken JH, Tonnissen E, Wissink W, van de Locht L, Overes I, et al. (2005). Expression of CIAP-1, CIAP-2 and survivin discriminates different types of lymphoid malignancies. Br J Haematol 100: 852–859.
17. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al. (2001). Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97: 2777–2783.
18. Gyrd-Hansen M, Meier P (2010). IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10: 561–574.
19. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376: 1164–1174.
20. Hamilton E, Pearce L, Morgan L, Robinson S, Wane V, Brennan P, et al. (2012). Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Br J Haematol 158: 589–599.
21. Happo L, Cragg MS, Phipson B, Haga JM, Jansen ES, Herold MJ, et al. (2010). Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 116: 5256–5267.
22. Harper N, MacFarlane M (2008). Recombinant TRAIL and TRAIL receptor analysis. Methods Enzymol 446: 293–313.
23. Hennessy EJ, Adam A, Aquila BM, Castriotta LM, Cook D, Hattersley M, et al. (2013). Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem 56: 9897–9919.
24. Huang DC, Strasser A (2000). BH3-Only proteins-essential initiators of apoptotic cell death. Cell 103: 839–842.
25. Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, van Lier RA, et al. (2004). CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 127: 404–415.
26. Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, et al. (2005). Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 106: 1742–1748.
27. Kitada S, Zapata JM, Andreeff M, Reed JC (1999). Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 106: 995–1004.
28. Kitada S, Zapata JM, Andreeff M, Reed JC (2000). Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96: 393–397.
29. Kitada S, Pedersen IM, Schimmer AD, Reed JC (2002). Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21: 3459–3474.
30. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG (2004). A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305: 1471–1474.
31. Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Döhner H, et al. (2009). A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 69: 8977–8986.
32. Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A, et al. (2013). CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. Cell Death Dis 4: e782.
33. Mace PD, Shirley S, Day CL (2010). Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ 17: 46–53.
34. Melarangi T, Zhuang J, Lin K, Rockliffe N, Bosanquet AG, Oates M, et al. (2012). Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. Cell Death Dis 3: e372.
35. Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid RM, Döhner H, et al. (2002). Tumour necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-κB/Rel–regulated inhibitors of apoptosis. Blood 100: 3749–3756.
36. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, et al. (2008). CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111: 5173–5181.
37. Pettitt AR, Sherrington PD, Cawley JC (1999). The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol 106: 1049–1051.
38. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, et al. (2009). Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 113: 856–865.
39. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, et al. (2004). Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104: 1428–1434.
40. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, et al. (2011). Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood 118: 4930–4934.
41. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, et al. (2012). Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119: 2854–2862.
42. Salvesen GS, Duckett CS (2002). IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401–410.
43. Schimmer AD (2004). Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64: 7183–7190.
44. Schimmer AD, Dalili S (2005). Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematology Am Soc Hematol Educ Program 2005: 215–219.
45. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, et al. (2004). Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5: 25–35.
46. Schliep S, Deckerb T, Schnellerb F, Wagnera H, Hacker G (2004). Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia. Exp Hematol 32: 556–562.
47. Silva KL, Vasconcellos DV, de Paula Castro ED, Coelho AM, Linden R, Maia RC (2006). Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 11: 277–285.
48. Srinivasula SM, Ashwell JD (2008). IAPs: what's in a name? Mol Cell 30: 123–135.
49. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J (1998). Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 188: 211–216.
50. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, et al. (2000). Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6: 1796–1803.
51. Vallat L, Magdelenat H, Merle-Beral H, Masdehors P, Potocki de Montalk G, Davi F, et al. (2003). The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 101: 4598–4606.
52. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131: 669–681.
53. Vaux DL, Silke J (2005). IAPs–the ubiquitin connection. Cell Death Differ 12: 1205–1207.
54. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. (2007). IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131: 682–693.
55. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, et al. (2009). Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113: 4403–4413.
56. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr (1998). NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680–1683.
57. Willis SN, Adams JM (2005). Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17: 617–625.
58. Yu JW, Shi Y (2008). FLIP and the death effector domain family. Oncogene 27: 6216–6227.
59. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S (2010). From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10: 37–50.
60. Zhuang J, Hawkins SF, Glenn MA, Lin K, Johnson GG, Carter A, et al. (2010). Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica 95: 110–118.